Excessive pricing: ECJ’s ruling in the Latvia’s case

Abuse of Dominant Position, ANTITRUST ENFORCEMENT, PUBLIC ANTITRUST ENFORCEMENTLeave a comment

On September 15, 2017, in case C-177/16, the European Court of Justice (“ECJ”) ruled that comparing prices between EU member states is a valid way to determine whether prices may be abusively excessive and competition regulators have a certain margin of discretion in deciding whether prices are excessive in the absence of a single adequate…

Excessive pricing: the European Commission opens formal investigation into Aspen Pharma’s pricing practices for cancer medicines

Abuse of Dominant Position, ANTITRUST ENFORCEMENT, Open Proceeding, PUBLIC ANTITRUST ENFORCEMENTLeave a comment

On 15 May 2017 the European Commission has opened its first excessive pricing investigation in the pharmaceutical industry to assess whether Aspen Pharma has abused a dominant position by charging excessive pricing for five life-saving cancer medicines. More specifically, the investigation concerns Aspen’s pricing practices for niche medicines used for treating cancer, such as hematologic…